HU Group subsidiary Fujirebio has launched the Lumipulse G GFAP assay, a new tool for neurological research, in the US.

The assay, for research use only, is designed for the quantitative glial fibrillary acidic protein (GFAP) measurement.

With the launch of this assay, the company further strengthens its neuro test menu.

The fully automated, random-access Lumipulse G GFAP assay is set to be released in Japan, Europe and other regions as of September 2024.

It enables the measurement of GFAP in human plasma and serum with a turnaround time of just 35 minutes. This assay is expected to advance research into neurological conditions such as multiple sclerosis and Alzheimer's disease.

The Lumipulse G platform allows professionals to measure GFAP in a user-friendly method.

It meets the necessary quality and regulatory requirements to support GFAP routine testing in combination with other tests from the neuro biomarker menu of Fujirebio.

Fujirebio president and CEO Goki Ishikawa said: “In 2023, we already introduced two new important neuro assays for RUO-based detection of neurofilament Light (NfL) and pTau 217.

“We continue our engagement in biomarker-based testing for neurological diseases with the Lumipulse G GFAP, affirming our commitment to play an essential partnering role in both research and clinical routine.”

In April 2023, Fujirebio expanded its fully automated blood-based biomarker portfolio with two completely automated assays for research use only.

The two assays, namely the Lumipulse G ApoE4 and Lumipulse G Pan-ApoE, are intended for the company’s completely automated LUMIPULSE G Systems.

Fujirebio is engaged in offering a range of assays for neurological conditions. The company collaborates globally with experts to innovate in neurodegenerative diagnostic tools.